Kornimate/medical-research-clean huggingface dataset:
pulmozyme for sjogren's associated cough

Conditions: Sjogren's Syndrome; Cough

Summary: patients with sjogren's disease have destruction of the mucus secreting cells in the airway. this manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. this study is aimed at determining whether the regular use of pulmozyme will result in decreased cough and improved quality of life.

patients with sjogren's disease have destruction of the mucus secreting cells in the bronchi. this manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. the investigators theorize that regular use of pulmozyme will result in decreased cough and improved quality of life, by improving mucus clearance. primary objective:to determine if the use of pulmozyme, twice a day improves cough-related quality of life or cough severity in patients with chronic cough due to sjogren's disease. secondary objectives: 1. to determine the dna content in sputum from patients with chronic cough due to sjogren's disease. 2. to determine the effect of pulmozyme use on pulmonary function in patients with chronic cough due to sjogren's disease. 3. to determine the safety of pulmozyme, taken twice a day in patients with chronic cough due to sjogren's disease.

Eligibility criteria:
inclusion criteria: * age 18 years or above with primary sjogren's disease (as defined by the american european consensus group criteria), and complaint of chronic cough. * able to give consent and anticipated ability to adhere to the study procedures. exclusion criteria: * diagnosis of copd, emphysema, asthma, chronic bronchitis, other clinically significant lung disease that is likely to cause cough. interstitial lung disease associated with sjogren's is not excluded. * cigarette use of greater than 20 pack years or regular use within 6 months * allergy or intolerance to pulmozyme. * acute respiratory infection or other acute respiratory illness during the prior month. * lcq greater than 17 and vas less than 3 cm at baseline (visit 1). * pregnancy or breast feeding.

Keywords: sjogren's syndrome cough
rehabilitation in patients with pulmonary fibrosis

Conditions: Rehabilitation

Summary: this study aims to explore the effects of exercise rehabilitation on the functional status of patients with pulmonary fibrosis, assessing both physical and psychological dimensions of health. by identifying significant improvements, we can contribute to the development of comprehensive rehabilitation strategies that enhance patient outcomes and foster a better quality of life for those affected by this challenging condition

program is essential for understanding its efficacy. functional status refers to an individual's ability to perform daily activities and maintain independence, which is particularly important for patients with chronic illnesses like pf. evaluating changes in functional status not only helps in determining the success of rehabilitation efforts but also provides insights into the overall impact of exercise on patients' quality of life.

Eligibility criteria:
inclusion criteria: * 1. \*\*diagnosis of pulmonary fibrosis:\*\* * patients must have a confirmed diagnosis of pulmonary fibrosis, as determined by clinical evaluation and imaging studies (e.g., high-resolution computed tomography). 2. \*\*age range:\*\* * participants should be adults aged 18 years and older to capture the adult population affected by the disease. 3. \*\*stable clinical condition:\*\* * patients must be in a stable clinical condition, defined as no exacerbations or significant changes in treatment for at least four weeks prior to enrollmen exclusion criteria: * 1. \*\*other significant lung diseases:\*\* * patients with concurrent respiratory conditions (e.g., chronic obstructive pulmonary disease, asthma, or lung cancer) that could confound the results. 2. \*\*acute exacerbations:\*\* * individuals experiencing an acute exacerbation of pulmonary fibrosis or any significant respiratory illness within four weeks prior to enrollment. 3. \*\*severe comorbidities:\*\* * patients with severe cardiovascular disease, uncontrolled hypertension, major neurological disorders, or musculoskeletal problems that would impede participation in exercise. 4. \*\*cognitive impairment:\*\* * individuals with cognitive impairments that prevent them from understanding the study procedures or following the rehabilitation program.
comparison of the effectiveness of exercise and vagus therapy in healthy individuals

Conditions: Healthy; Activity, Motor; Sleep; Stress, Physiological; Fatigue

Summary: objective: sympathetic activity starts to increase during exercise. at the end of the exercise, while sympathetic activation decreases, parasympathetic activity increases. sympathetic and parasympathetic excursions achieve homeostasis. most of the parasympathetic activity effects are vagus code. it is aimed to compare the comparison of exercise and vagus therapy in these healthy individuals.

objective: the aim of this study is to compare the effectiveness of stabilization exercise and vagus nerve stimulation on healthy individuals. research method: this randomized controlled trial; it is planned to be carried out on students and administrative / academic staff at gümüşhane university. first of all, the application will be explained to the individuals and online consent will be obtained from the individuals for the application. group 1 will be given stabilization exercises. vagus therapy will be applied to group 2. group 3 will be followed as a control group and no application will be made. evaluations; 1. evaluation of autonomous parameters; it was planned to measure pulse and heart rate variability. 2. chest circumference measurement 3. in addition, it is planned to use "perceived stress scale", "pitsburg sleep quality scale" and "fatigue severity scale" questionnaires. all individuals were planned to be evaluated before, after and 1 month after the application.

Eligibility criteria:
inclusion criteria: * healthy volunteer individuals (female and male), * individuals between the ages of 18-50, * obtaining the necessary consent for the study, * no trauma or surgery history in the last 6 months, * does not have any chronic disease (obesity, diabetes, hypertension, osteoporosis) exclusion criteria: * individuals not wanting to continue working. * individuals having disability during the work process

Keywords: exercise vagus therapy autonomic nervous system
open-label, randomized trial to determine the effect of icodextrin versus dextrose (dianeal 2.5%) in homa ir

Conditions: End Stage Renal Disease; Continuous Ambulatory Peritoneal Dialysis

Summary: phase iv post-marketing study to evaluate the effect of extraneal on the homa index in non-diabetic capd patients over the long-dwell exchange. the purpose of the study is to investigate if the use of extraneal (which is a mixture of high weight glucose polymers), instead of glucose-based solutions such as dianeal is going to lower the homa index in non-diabetic capd patients.


Eligibility criteria:
inclusion criteria: * must be over 18-years old and under 75-years old * peritoneal equilibration test (pet) result of high, high average or low average transport * non-diabetic patient * be in continuous ambulatory peritoneal dialysis (capd) * prevalent patients that have been in peritoneal dialysis at least 30 days * wish to participate exclusion criteria: * have a charlson score of \>7 and have a life expectancy of less than 12 months * hiv positive * present with peritonitis in the month prior to randomisation * present with cardiovascular, metabolic or infection complications that have required hospitalisation in the month prior to the randomisation * have active cancer * pregnant women * patients with known allergy to starch-based polymer * patients who have a significant psychiatric disorder or mental disability that could interfere with the patient´s ability to provide informed consent and comply with the protocol procedures * women incapable of maintaining an effective and accepted contraception method
changes in hemorrhage with prophylactic oxytocin for dilation and evacuation

Conditions: Hemorrhage

Summary: the purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (d\&e) in the clinic setting.


Eligibility criteria:
inclusion criteria: * clinic-based d\&e at 18 weeks gestational age and above * speaks english or spanish exclusion criteria: * refuses iv * history of coagulopathy * anticoagulant use in the preceding five days * chorioamnionitis or sepsis * suspected placenta accreta spectrum * intrauterine fetal demise * multiple gestation * use of misoprostol for cervical preparation
exploration of lymph node metastasis and tumor deposit in the posterior gastric mesentery for distal gastric cancer

Conditions: Gastric Carcinoma

Summary: this study aims to evaluate lymph node metastasis and tumor deposit in the posterior gastric mesentery following distal gastrectomy with d2 lymphadenectomy plus complete mesogastric excision (cme) in gastric cancer.

since 1997, the ajcc has been using the number of lymph node metastases (pn staging) as a crucial indicator to assess the prognosis of gastric cancer patients. this system has been continuously updated, widely accepted by the global oncology community, and confirmed for its feasibility, applicability, convenience, and reproducibility. the number of metastatic lymph nodes in radical resection specimens of gastric cancer patients is the total count of lymph nodes with metastasis and is a key focus of postoperative pathological examination. d2 lymphadenectomy has become the standard operative procedure for advanced resectable gastric cancer and certain early-stage gastric cancers (diagnosed preoperatively with lymph node metastases). for advanced gastric cancer, there is growing evidence that the ideal surgical approach should involve d2 lymphadenectomy plus cme. in distal gastrectomy, the number of lymph nodes removed in d2 lymphadenectomy plus cme is significantly higher than in d2 dissection. additionally, patients in the d2+cme group exhibit better long-term outcomes compared to the d2 group (dcgc01 study). performing d2+cme surgery for distal gastric cancer involves the resection of the five major mesentery, including the posterior gastric mesentery, which may aid in thorough lymph node clearance and reduce cancer spillage. the posterior gastric mesentery comprises the no.11p and part of the no.11d lymph nodes. however, only the no.11p lymph nodes are resected in traditional d2 lymphadenectomy, resulting in incomplete lymph node clearance and postoperative tumor recurrence. hence, the primary objective of this study is to examine lymph node metastasis in the posterior gastric mesentery following d2+cme in patients undergoing distal gastrectomy, aiming to offer evidence-based medical insights for standardizing surgical approaches in gastric cancer management.

Eligibility criteria:
inclusion criteria: 1. aged older than 18 years and younger than 85 years 2. primary gastric adenocarcinoma confirmed by preoperative pathology result 3. ct2-4n0-3m0 at preoperative evaluation according to the american joint 8 committee on cancer (ajcc) cancer staging manual 7th edition 4. patients who received distal gastrectomy with d2 lymphadenectomy plus complete mesogastric excision 5. american society of anesthesiologists (asa) class i, ii, or iii 6. written informed consent exclusion criteria: 1. negative preoperative biopsy 2. too late tumour stage or metastasis (ct4b/m1) 3. bmi\>30 kg/m2 4. total gastrectomy or proximal gastrectomy 5. previous neoadjuvant chemotherapy or radiotherapy 6. previous upper abdominal surgery 7. combined with other malignant diseases 8. reject operation

Keywords: gastric cancer lymph node dissection posterior gastric mesentery lymph node metastasis
a study of once-monthly intravenous mircera in hemodialysis patients with chronic renal anemia.

Conditions: Anemia

Summary: this single arm study will assess the long-term maintenance of hemoglobin levels, safety and tolerability of once-monthly intravenous administration of mircera in hemodialysis patients with chronic renal anemia. patients currently receiving darboepoetin alfa or epoetin alfa maintenance treatment will receive intravenous mircera at a starting dose of 120, 200 or 360 micrograms/4 weeks (based on the esa dose administered on week-1). subsequent doses will be adjusted to maintain hemoglobin levels within the target range of 10.5-12.5g/dl. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * chronic renal anemia; * regular long-term hemodialysis therapy with the same mode of dialysis for \>=3 months; * continuous iv or sc maintenance esa treatment during previous 2 months. exclusion criteria: * transfusion of red blood cells during previous 2 months; * significant acute or chronic bleeding, such as overt gastrointestinal bleeding; * active malignant disease (except non-melanoma skin cancer).
gut microbiome components predict response to neoadjuvant therapy in her2-positive breast cancer patients : a prospective study

Conditions: Breast Cancer

Summary: in this study the characteristics and alterations of the gut microbiome during neoadjuvant therapy for her2-positive breast cancer patients are studied, as well as the relation between the gut microbiome and probability of pcr.

although systemic treatment for early stage her2-positive breast cancer is becoming increasingly effective, resistance and side effects of current treatment modalities are substantial. there is an urgent need for novel therapies, and in addition, better predictive tools are needed to select the right drug to the right patient. new data suggest that modulation of the microbiome of the gut might provide opportunities to increase anti-tumor efficacy of cancer therapies. a better understanding of the composition, function and dynamics of the gut microbiome before and during trastuzumab-containing neoadjuvant treatment might help to identify factors that can be influenced during the treatment of patients with primary her2-positive bc . this study will prospectively enroll 100 participants with newly diagnosed her2-positive breast cancer patients undergoing standard of care trastuzumab-containing neoadjuvant treatment and correlate gut microbiome composition with pcr. patients will be treated with the standard of care neoadjuvant therapy. stool and peripheral blood (pb) samples will be collected at time of consent for therapy, mid-treatment, after the completion of neoadjuvant treatment (at the discretion of the medical oncologist). correlation of changes in gut microbiome and metabolic changes, as well as inflammation and microbiome metabolites, will be assessed and possible connection with pcr and side effects will be explored.

Eligibility criteria:
inclusion criteria: 1. female, presenting for the first time with operable breast cancer, who had not received any previous treatment for an invasive malignancy. 2. primary tumor greater than (\>) 2 cm in diameter. 3. age ≥ 18 years and \< 70 years. 4. eastern cooperative oncology group (ecog) performance status less than or equal to (\</=) 1. 5. baseline left ventricular ejection fraction (lvef) greater than or equal to (\>/=) 55% 6. availability of tumor tissue specimen after surgery. 7. histologically proven diagnosis of breast cancer. 8. patients have her2-positive disease. her2-positive disease was defined as follows: disease which overexpresses her-2 by immunohistochemistry (ihc) 3+ and/or has her2 amplification according to fluorescence in situ hybridization (fish). 9. had hormonal receptors (er and pgr) assessed. 10. signed informed consent. 11. able to comply with the protocol. exclusion criteria: 1. prior ipsilateral breast surgery, ipsilateral radiotherapy, hormonal therapy or systemic chemotherapy 2. prolonged antibiotic treatment \> 10 days within 1 month of neoadjuvant chemotherapy as prevention or suppression of an ongoing infection 3. uncontrolled inflammatory bowel disease 4. pregnant

Keywords: her2-positive neoadjuvant microbiome
accuracy of the d-dimer assay for the exclusion of pulmonary embolism in a high risk oncologic population

Conditions: Cancer; Pulmonary Embolism

Summary: the purpose of this study is to see if a blood test (d-dimer) is as precise as the ct scan for the detection of clots. a pulmonary embolism is an obstruction of the blood vessels in your lungs usually due to a blood clot that travels to the lungs usually from the leg. research has shown that the results of a specific blood test (d-dimer) can be used instead of a ct scan to diagnose clots. d-dimer is a valuable diagnostic marker in either detecting the presence of or monitoring the progress of blood clots. d-dimer assays have proven to be a beneficial diagnostic tool in the evaluation of patients with suspected pulmonary embolism (pe).


Eligibility criteria:
inclusion criteria: * all patients evaluated in the urgent care center and determined to need with ct pulmonary angiogram to rule out pulmonary embolism based on signs and symptoms such as dyspnea, pleuritic chest pain, tachycardia, and/or pulse oxygen desaturation will be included. exclusion criteria: * inability to obtain ct pulmonary angiogram secondary to lack of iv access, contrast allergy or lack of consent. * ct pulmonary angiogram not done with routine protocol for rule out pulmonary embolism. * less than 21 years of age

Keywords: any cancer suspected pulmonary embolism
study to evaluate the non-inferiority of cavir in hbeag(+)chronic hepatitis b patients treated with baraclude

Conditions: Chronic Hepatitis B

Summary: open-labeled, prospective, randomized, multi-center, interventional, phase iv study.

the purpose of this study is to evaluate the non-inferiority and safety in terms of hbv dna undetectability comparing baraclude tab. in hbeag(+) chronic hepatitis b patients treated with long-term baraclude tab.

Eligibility criteria:
inclusion criteria: * patients (over the19 years of age) currently taking baraclude® monotherapy for chronic hbv infection for at least 24 month with \< hbv dna 60 iu/ml level, hbeag positive and hbeab negative status at screening. exclusion criteria: * patients are diagnosed hepatitis cancer and hepatocellular carcinoma (hcc) * patient has concomitant other chronic viral infection (hav/hepatitis c virus (hcv)/hepatitis d virus(hdv)/hiv) * patient had documented resistance mutations at any time before or at screening * patient has clinically confirmed alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency and wilson's disease. * patient has received antiviral agent including interferon other than baraclude within 24 months before screening for this study. * patient has received immunosuppressive agent within 24 weeks before screening or corticosteroids for 4 weeks. * clinical signs as indicated by any one of the following: ccr(cockroft-gault) \ 3.0 mg/dl, albumin \ inr 2.3 * patient is pregnant or breastfeeding or willing to be pregnant * patient has malignancy except for thyroid cancer and borderline malignancy.a history of treated malignancy is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding five years

Keywords: entecavir
the effectiveness of regular exercise on improving sleep in older adults

Conditions: Sleep Initiation and Maintenance Disorders; Sleep Disorders, Intrinsic

Summary: this study will evaluate the effect of regular aerobic exercise on improving sleep in older adults with moderate difficulty sleeping.

sleep deprivation is a common problem among older adults. it is often at the root of increased mortality and some psychiatric disorders. regular participation in a medium-intensity exercise regimen may help people sleep better. this study will assess the effectiveness of a regular exercise program on improving sleep in older adults with moderate difficulty sleeping. participants will be randomly assigned to one of two conditions. one group will partake in a moderate-intensity physical activity training regimen. the other group will act as a non-exercise attention-control comparison group. each group will undergo its assigned treatment for 12 months. sleep quantity and quality will be measured objectively using in-home polysomnography. subjective sleep quality and health-related quality of life measures will be evaluated with questionnaires. all measurements will be performed at the beginning of the study, month 6, and month 12.

Eligibility criteria:
inclusion criteria: * moderate difficulty sleeping unrelated to a physical illness or psychopathology (determined by the sleep questionnaire and assessment of wakefulness) * currently not physically active on a regular basis * body mass index less than 38 exclusion criteria: * currently physically active on a regular basis * diagnosed with a clinically significant sleep disorder * mild or no sleep complaints (determined by the sleep questionnaire and assessment of wakefulness) * unstable on medications * current smoker * consumes more than three alcoholic beverages per day * medical condition that may limit participation in moderate-intensity exercise * diagnosed with clinical psychopathology

Keywords: sleep exercise older adults
differential metabolic effects of fenofibrate and fatty acid

Conditions: Hypertriglyceridemia

Summary: the investigators hypothesize that fenofibrate and fatty acid may have different metabolic effects in hypertriglyceridemic patients


Eligibility criteria:
inclusion criteria: * hypertriglyceridemia exclusion criteria: * overt liver disease chronic renal failure hypothyroidism myopathy uncontrolled diabetes severe hypertension

Keywords: insulin resistance